The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium

DMM Disease Models and Mechanisms

Volumn 5, Issue 1, 2012, Pages 115-124

  Chang, Pishan ^a   Orabi, Benoit ^a   Deranieh, Rania M ^b   Dham, Manik ^a   Hoeller, Oliver ^c   Shimshoni, Jakob A ^d   Yagen, Boris ^d   Bialer, Meir ^d   Greenberg, Miriam L ^b   Walker, Matthew C ^e   Williams, Robin S B ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; INOSITOL; MEDIUM CHAIN FATTY ACID; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3 KINASE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DICTYOSTELIUM; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; IN VITRO STUDY; MYCETOZOA; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

ANIMALS; ANTICONVULSANTS; DICTYOSTELIUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; INOSITOL; MODELS, BIOLOGICAL; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHATIDYLINOSITOLS; RATS; SIGNAL TRANSDUCTION; TIME FACTORS; VALPROIC ACID;

DICTYOSTELIUM; MAMMALIA; RATTUS;

EID: 84862907498     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.008029     Document Type: Article

References (46)

1. Armand, V., Louvel, J., Pumain, R. and Heinemann, U. (1998). Effects of new valproate derivatives on epileptiform discharges induced by pentylenetetrazole or low Mg2+ in rat entorhinal cortex-hippocampus slices. Epilepsy Res. 32, 345-355. (Pubitemid 28518240)
2. Backman, S. A., Stambolic, V., Suzuki, A., Haight, J., Elia, A., Pretorius, J., Tsao, M. S., Shannon, P., Bolon, B., Ivy, G. O. et al. (2001). Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 29, 396-403. (Pubitemid 34326689)
3. Bialer, M. and Yagen, B. (2007). Valproic acid: second generation. Neurotherapeutics 4, 130-137. (Pubitemid 46107326)
4. Boeckeler, K., Adley, K., Xu, X., Jenkins, A., Jin, T. and Williams, R. S. (2006). The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dictyostelium discoideum. Eur. J. Cell Biol. 85, 1047-1057. (Pubitemid 44317602)
5. Chapman, A. G., Meldrum, B. S. and Mendes, E. (1983). Acute anticonvulsant activity of structural analogues of valproic acid and changes in brain GABA and aspartate content. Life Sci. 32, 2023-2031. (Pubitemid 13114083)
6. Drayer, A. L., Van der Kaay, J., Mayr, G. W. and Van Haastert, P. J. (1994). Role of phospholipase C in Dictyostelium: formation of inositol 1,4,5-trisphosphate and normal development in cells lacking phospholipase C activity. EMBO J. 13, 1601-1609. (Pubitemid 24114711)
7. DSMV, IV (2000). American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association.
8. Eickholt, B. J., Towers, G., Ryves, W. J., Eikel, D., Adley, K., Ylinen, L., Chadborn, N., Harwood, A., Nau, H. and Williams, R. S. (2005). Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, GSK-3β inhibition and viral replication-A screening approach for new bipolar disorder drugs based on the valproic acid core structure. Mol. Pharmacol. 67, 1-8.
9. Einat, H., Tian, F., Belmaker, R. H. and Frost, J. W. (2008). Myo-inositol-1-phosphate (MIP) synthase inhibition: in-vivo study in rats. J. Neural Transm. 115, 55-58.
10. Guo, K., Nichol, R., Skehel, P., Dormann, D., Weijer, C. J., Williams, J. G. and Pears, C. (2001). A Dictyostelium nuclear phosphatidylinositol phosphate kinase required for developmental gene expression. EMBO J. 20, 6017-6027. (Pubitemid 33049277)
11. Hallcher, L. M. and Sherman, W. R. (1980). The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255, 10896-10901. (Pubitemid 11171746)
12. Heinemann, U., Draguhn, A., Ficker, E., Stabel, J. and Zhang, C. L. (1994). Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia 35 Suppl. 5, S10-S21. (Pubitemid 24274695)
13. Hoeller, O. and Kay, R. R. (2007). Chemotaxis in the absence of PIP3 gradients. Curr. Biol. 17, 813-817. (Pubitemid 46635122)
14. Honack, D. and Loscher, W. (1992). Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res. 13, 215-221. (Pubitemid 23000924)
15. Johnson, C. B., Wong, E. and Birch, E. J. (1977). Analysis of 4-methyloctanoic acid and other medium chain-length fatty acid constituents of ovine tissue lipids. Lipids 12, 340-347. (Pubitemid 8096382)
16. Keane, P. E., Simiand, J., Mendes, E., Santucci, V. and Morre, M. (1983). The effects of analogues of valproic acid on seizures induced by pentylenetetrazol and GABA content in brain of mice. Neuropharmacology 22, 875-879. (Pubitemid 13029081)
17. King, J., Keim, M., Teo, R., Weening, K. E., Kapur, M., McQuillan, K., Ryves, J., Rogers, B., Dalton, E., Williams, R. S. et al. (2010). Genetic control of lithium sensitivity and regulation of inositol biosynthetic genes. PLoS. ONE 5, e11151.
18. King, J. S., Teo, R., Ryves, J., Reddy, J. V., Peters, O., Orabi, B., Hoeller, O., Williams, R. S. and Harwood, A. J. (2009). The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells. Dis. Model. Mech. 2, 306-312.
19. Kortholt, A. and van Haastert, P. J. (2008). Highlighting the role of Ras and Rap during Dictyostelium chemotaxis. Cell. Signal. 20, 1415-1422.
20. Lagace, D. C., O'Brien, W. T., Gurvich, N., Nachtigal, M. W. and Klein, P. S. (2005). Valproic acid: how it works. Or not. Clin. Neurosci. Res. 4, 215-225.
21. Liu, M. J. and Pollack, G. M. (1994). Pharmacokinetics and pharmacodynamics of valproate analogues in rats. IV. Anticonvulsant action and neurotoxicity of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid. Epilepsia 35, 234-243.
22. Loscher, W. and Nau, H. (1985). Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 24, 427-435. (Pubitemid 15096713)
23. Ludtmann, M. H., Boeckeler, K. and Williams, R. S. (2011). Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder. Semin. Cell Dev. Biol. 22, 105-113.
24. Maslanski, J. A. and Busa, W. B. (1990). A sensitive and specific mass assay for myoinositol and inositol phosphates. In Methods in Inositide Research (ed. R. F. Irvin), pp. 113-126. New York: Raven Press Ltd.
25. Meunier, H., Carraz, G., Neunier, Y., Eymard, P. and Aimard, M. (1963). Pharmacodynamic properties of N-dipropylacetic acid. Therapie 18, 435-438.
26. Nalivaeva, N. N., Belyaev, N. D. and Turner, A. J. (2009). Sodium valproate: an old drug with new roles. Trends Pharmacol. Sci. 30, 509-514.
27. Nau, H. and Loscher, W. (1986). Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam. Appl. Toxicol. 6, 669-676. (Pubitemid 16110138)
28. Pawolleck, N. and Williams, R. S. (2009). Quantifying in vivo phosphoinositide turnover in chemotactically competent Dictyostelium cells. Methods Mol. Biol. 571, 283-290.
29. Sasaki, A. T. and Firtel, R. A. (2006). Regulation of chemotaxis by the orchestrated activation of Ras, PI3K, and TOR. Eur. J. Cell Biol. 85, 873-895. (Pubitemid 44334734)
30. Shaltiel, G., Shamir, A., Shapiro, J., Ding, D., Dalton, E., Bialer, M., Harwood, A. J., Belmaker, R. H., Greenberg, M. L. and Agam, G. (2004). Valproate decreases inositol biosynthesis. Biol. Psychiatry 56, 868-874. (Pubitemid 39575461)
31. Shaltiel, G., Dalton, E. C., Belmaker, R. H., Harwood, A. J. and Agam, G. (2007a). Specificity of mood stabilizer action on neuronal growth cones. Bipolar Disord. 9, 281-289. (Pubitemid 46547122)
32. Shaltiel, G., Mark, S., Kofman, O., Belmaker, R. H. and Agam, G. (2007b). Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol. Rep. 59, 402-407. (Pubitemid 47554819)
33. Shimshoni, J. A., Dalton, E. C., Jenkins, A., Eyal, S., Kwan, K., Williams, R. S., Pessah, N., Yagen, B., Harwood, A. J. and Bialer, M. (2007). The effects of CNS-active Valproic acid constitutional isomers, cyclopropyl analogues and amide derivatives on neuronal growth cone behaviour. Mol. Pharmacol. 71, 884-892. (Pubitemid 46294100)
34. Storey, N. M., O'Bryan, J. P. and Armstrong, D. L. (2002). Rac and Rho mediate opposing hormonal regulation of the ether-a-go-go-related potassium channel. Curr. Biol. 12, 27-33. (Pubitemid 34063350)
35. Terbach, N. and Williams, R. S. (2009). Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 37, 1126-1132.
36. Terbach, N., Shah, R., Kelerman, R., Klein, P. S., Gordienko, D. V., Brown, N. A., Wilkinson, C. J. and Williams, R. S. B. (2011). Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid. J. Cell Sci. 124, 2267-2276.
37. Tokuoka, S. M., Saiardi, A. and Nurrish, S. J. (2008). The mood stabilizer valproate inhibits both inositol- and diacylglycerol-signaling pathways in Caenorhabditis elegans. Mol. Biol. Cell 19, 2241-2250.
38. Vaden, D. L., Ding, D., Peterson, B. and Greenberg, M. L. (2001). Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J. Biol. Chem. 276, 15466-15471.
39. Van Rooijen, L. A., Vadnal, R., Dobard, P. and Bazan, N. G. (1986). Enhanced inositide turnover in brain during bicuculline-induced status epilepticus. Biochem. Biophys. Res. Commun. 136, 827-834. (Pubitemid 16075364)
40. Williams, R. S. (2009). Employing multiple models, methods and mechanisms in bipolar disorder research. Biochem. Soc. Trans. 37, 1077-1079.
41. Williams, R. S., Boeckeler, K., Graf, R., Muller-Taubenberger, A., Li, Z., Isberg, R. R., Wessels, D., Soll, D. R., Alexander, H. and Alexander, S. (2006). Towards a molecular understanding of human diseases using Dictyostelium discoideum. Trends Mol. Med. 12, 415-424. (Pubitemid 44291568)
42. Williams, R. S. B. (2005a). Pharmacogenetics in model systems: Defining a common mechanism of action for mood stabilisers. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 1029-1037.
43. Williams, R. S. B. (2005b). Prolyl oligopeptidase and bipolar disorder. Clin. Neurosci. Res. 4, 233-242.
44. Williams, R. S. B., Eames, M., Ryves, W. J., Viggars, J. and Harwood, A. J. (1999). Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J. 18, 2734-2745. (Pubitemid 29233946)
45. Williams, R. S. B., Cheng, L., Mudge, A. W. and Harwood, A. J. (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295. (Pubitemid 34534711)
46. Xu, X., Muller-Taubenberger, A., Adley, K. E., Pawolleck, N., Lee, V. W., Wiedemann, C., Sihra, T. S., Maniak, M., Jin, T. and Williams, R. S. (2007). Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot. Cell 6, 899-906. (Pubitemid 46983290)